GlaxoSmithKline plc (GSK) Receives “Buy” Rating from HSBC Holdings plc
A number of other analysts have also commented on GSK. BNP Paribas reaffirmed an underperform rating and set a GBX 1,520 ($18.77) price objective on shares of GlaxoSmithKline plc in a research note on Wednesday, December 21st. Shore Capital reaffirmed a hold rating on shares of GlaxoSmithKline plc in a research note on Wednesday, December 21st. JPMorgan Chase & Co. reaffirmed a neutral rating on shares of GlaxoSmithKline plc in a research note on Tuesday, February 7th. Liberum Capital reaffirmed a buy rating and set a GBX 1,900 ($23.47) price objective on shares of GlaxoSmithKline plc in a research note on Thursday, January 19th. Finally, Credit Suisse Group AG reaffirmed a neutral rating and set a GBX 1,750 ($21.61) price objective on shares of GlaxoSmithKline plc in a research note on Thursday, February 9th. Three equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have issued a buy rating to the company. GlaxoSmithKline plc currently has a consensus rating of Hold and an average target price of GBX 1,744.73 ($21.55).
Shares of GlaxoSmithKline plc (LON:GSK) opened at 1681.00 on Wednesday. GlaxoSmithKline plc has a 1-year low of GBX 1,363.00 and a 1-year high of GBX 1,745.56. The stock’s market capitalization is GBX 81.83 billion. The firm’s 50-day moving average is GBX 1,626.62 and its 200 day moving average is GBX 1,592.90.
Your IP Address:
The firm also recently disclosed a dividend, which will be paid on Thursday, April 13th. Investors of record on Thursday, February 23rd will be given a dividend of GBX 23 ($0.28) per share. This represents a yield of 1.47%. The ex-dividend date of this dividend is Thursday, February 23rd. This is a positive change from GlaxoSmithKline plc’s previous dividend of $19.00.
In related news, insider Victoria Whyte sold 4,820 shares of the firm’s stock in a transaction that occurred on Thursday, February 9th. The shares were sold at an average price of GBX 1,576 ($19.46), for a total transaction of £75,963.20 ($93,816.48). Also, insider Vivienne Cox acquired 342 shares of the business’s stock in a transaction that occurred on Wednesday, February 8th. The shares were acquired at an average cost of GBX 1,555 ($19.20) per share, for a total transaction of £5,318.10 ($6,567.99). In the last ninety days, insiders have purchased 471 shares of company stock worth $786,697 and have sold 52,038 shares worth $84,442,106.
GlaxoSmithKline plc Company Profile
GlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company’s segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily email newsletter.